CN112972547B - Traditional Chinese medicine composition for treating qi and blood deficiency syndrome and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for treating qi and blood deficiency syndrome and preparation method and application thereof Download PDFInfo
- Publication number
- CN112972547B CN112972547B CN201911298448.5A CN201911298448A CN112972547B CN 112972547 B CN112972547 B CN 112972547B CN 201911298448 A CN201911298448 A CN 201911298448A CN 112972547 B CN112972547 B CN 112972547B
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- medicine composition
- parts
- prescription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 89
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 239000008280 blood Substances 0.000 title claims abstract description 66
- 230000007812 deficiency Effects 0.000 title claims abstract description 51
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 15
- 210000004369 blood Anatomy 0.000 title abstract description 61
- 238000002360 preparation method Methods 0.000 title abstract description 38
- 239000000463 material Substances 0.000 claims abstract description 29
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 27
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 26
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 26
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 26
- 239000008187 granular material Substances 0.000 claims abstract description 25
- 238000002156 mixing Methods 0.000 claims abstract description 15
- 235000006545 Ziziphus mauritiana Nutrition 0.000 claims abstract description 8
- 235000008529 Ziziphus vulgaris Nutrition 0.000 claims abstract description 8
- 244000182216 Mimusops elengi Species 0.000 claims abstract 2
- 235000006533 astragalus Nutrition 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 31
- ZZAJQOPSWWVMBI-UHFFFAOYSA-N Calycosin Natural products C1=C(O)C(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZZAJQOPSWWVMBI-UHFFFAOYSA-N 0.000 claims description 24
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 24
- -1 calycosin glucoside Chemical class 0.000 claims description 24
- 229930182478 glucoside Natural products 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 20
- 241000382455 Angelica sinensis Species 0.000 claims description 20
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 20
- 235000001785 ferulic acid Nutrition 0.000 claims description 20
- 229940114124 ferulic acid Drugs 0.000 claims description 20
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 20
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 20
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 claims description 19
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 claims description 19
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 15
- 230000037396 body weight Effects 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 239000008518 lycium barbarum polysaccharide Substances 0.000 claims description 11
- 238000009835 boiling Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 9
- 239000002674 ointment Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 7
- 241000045403 Astragalus propinquus Species 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 235000012907 honey Nutrition 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 38
- 244000061520 Angelica archangelica Species 0.000 abstract description 25
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract description 25
- 239000000284 extract Substances 0.000 abstract description 18
- 238000002512 chemotherapy Methods 0.000 abstract description 14
- 230000036039 immunity Effects 0.000 abstract description 12
- 210000000952 spleen Anatomy 0.000 abstract description 7
- 238000005728 strengthening Methods 0.000 abstract description 7
- 238000012545 processing Methods 0.000 abstract description 6
- 206010028980 Neoplasm Diseases 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 229940107666 astragalus root Drugs 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 abstract description 4
- 210000003734 kidney Anatomy 0.000 abstract description 4
- 210000004185 liver Anatomy 0.000 abstract description 4
- 238000001959 radiotherapy Methods 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 2
- 241001061264 Astragalus Species 0.000 description 34
- 210000004233 talus Anatomy 0.000 description 34
- 239000000047 product Substances 0.000 description 33
- 239000000243 solution Substances 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 208000007502 anemia Diseases 0.000 description 26
- 240000002624 Mespilus germanica Species 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 23
- 208000024891 symptom Diseases 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 238000000465 moulding Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 7
- 235000015468 Lycium chinense Nutrition 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 7
- 206010016256 fatigue Diseases 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000012085 test solution Substances 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 244000241838 Lycium barbarum Species 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 244000183685 Citrus aurantium Species 0.000 description 5
- 235000007716 Citrus aurantium Nutrition 0.000 description 5
- 235000015459 Lycium barbarum Nutrition 0.000 description 5
- 244000241872 Lycium chinense Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000004820 blood count Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- 229940126680 traditional chinese medicines Drugs 0.000 description 5
- 241000132012 Atractylodes Species 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 240000005373 Panax quinquefolius Species 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 238000000691 measurement method Methods 0.000 description 4
- 210000004976 peripheral blood cell Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 235000002722 Dioscorea batatas Nutrition 0.000 description 3
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 3
- 240000001811 Dioscorea oppositifolia Species 0.000 description 3
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 3
- 206010026749 Mania Diseases 0.000 description 3
- 240000000249 Morus alba Species 0.000 description 3
- 235000008708 Morus alba Nutrition 0.000 description 3
- 241000405414 Rehmannia Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000012088 reference solution Substances 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000011003 system suitability test Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 244000144730 Amygdalus persica Species 0.000 description 2
- 241000380450 Danaus melanippus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000545744 Hirudinea Species 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 206010024642 Listless Diseases 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 240000004980 Rheum officinale Species 0.000 description 2
- 235000008081 Rheum officinale Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000255626 Tabanus <genus> Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 235000004879 dioscorea Nutrition 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000017971 listlessness Diseases 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241000427159 Achyranthes Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 241000759833 Cornus officinalis Species 0.000 description 1
- 241000110637 Cuscuta chinensis Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000123589 Dipsacus Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 241000212322 Levisticum officinale Species 0.000 description 1
- 241000830535 Ligustrum lucidum Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 244000152640 Rhipsalis cassutha Species 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000316342 Taxillus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000009661 fatigue test Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000001645 levisticum officinale Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating qi and blood deficiency syndrome and a preparation method and application thereof, wherein the traditional Chinese medicine composition comprises, by weight, 25-35 parts of astragalus root or an extract thereof, 5-7 parts of angelica or an extract thereof, 8-12 parts of Chinese date or an extract thereof, 5-10 parts of medlar or an extract thereof, 5-8 parts of dried orange peel or an extract thereof, and the raw material components can be respectively prepared into paste or granule preparations of the traditional Chinese medicine composition after processing, extracting, concentrating and mixing auxiliary materials. The whole formula has the effects of nourishing liver and kidney, strengthening spleen and regulating qi, tonifying defensive qi and strengthening body resistance and consolidating constitution, thereby enhancing the immunity of organisms, and is mainly suitable for people with high working pressure, excessive fatigue, postpartum qi and blood deficiency and low immunity caused by cancer radiotherapy and chemotherapy.
Description
Technical Field
The invention relates to a traditional Chinese medicine composition for treating qi and blood deficiency symptoms and a preparation method and application thereof, in particular to a traditional Chinese medicine compound composition of astragalus and Chinese angelica for treating qi and blood deficiency symptoms and a preparation method and application thereof, belonging to the technical field of traditional Chinese medicines.
Background
Deficiency of both qi and blood refers to the condition of deficiency of both qi and blood, i.e., the pathological condition of both qi deficiency and blood deficiency, which is caused by both qi and blood deficiency, and may be caused by deficiency of both qi and blood, or by deficiency of both blood. The clinical manifestations of qi deficiency and blood deficiency are that the symptoms are qi deficiency and lazy speaking, listlessness, spontaneous perspiration, dizziness, palpitation and insomnia, pale complexion and sallow complexion, etc. It is indicated for both qi and blood deficiency.
The traditional Chinese medicine classical prescription preparation "Danggui Buxue Tang" is firstly carried in Jinli Yuan Sheng "internal and external injury distinguished confusion" and the original prescription describes: for treating muscle heat, dryness heat, thirst, red eyes, red faces, and excessive and deficient pulse, it is indicated for all kinds of severe depression. "Neijing" is: blood deficiency due to pulse deficiency. And (3) cloud: the fever due to blood deficiency is manifested as white tiger, but the pulse is not long enough to identify the ear, and the white tiger Shang Bi is mistakenly taken to die. The disease is caused by hunger and fatigue. The prescription is prepared from radix astragali (one or two), radix Angelicae sinensis (washed with wine, and two pieces) and mouth, by decocting with water, and removing residues. Warm taking and hollow before eating. Has effects of invigorating qi and promoting blood production, and can be used for treating heat syndrome due to blood deficiency Yang Fu. Modern medical research such as: wang Yan the effects of different components in the Angelica sinensis blood-replenishing decoction on the immune function of normal and blood deficiency mice, and the researches on the components of the Angelica sinensis blood-replenishing decoction for promoting hematopoiesis and the effects thereof, which are described in Chinese J.Chinese medicine (2002, 27 (1): 50-53), are equally described in Chinese herbal medicines (2002, 33 (2): 138), are proved to have the effects of improving the blood system function, regulating immunity, protecting liver, resisting oxidation and the like, and can also be used for postoperative conditioning of various cancer patients. However, the Dang Gui blood-replenishing decoction has only the effects of tonifying qi and producing blood, and is mainly characterized by weak constitution, malnutrition, listlessness, fatigue and weakness, appetite reduction, sleep disorder and the like in combination with the condition of low immunity of modern diseases. Therefore, the Chinese angelica blood replenishing decoction only solves the symptoms of physical weakness, sleep disorder, general weakness and the like, but has the defects of poor appetite, poor nutrition and the like.
In order to better adapt to the evolution of modern diseases, the prior patent literature also describes a plurality of pharmaceutical compositions for treating qi and blood deficiency symptoms, which have the effects of reinforcing spleen and kidney, enhancing immunity, adjusting human body functions and the like on the basis of the Chinese angelica blood replenishing decoction, such as: patent document CN106310209a (a traditional Chinese medicine preparation for treating deficiency of both qi and blood and a preparation method thereof, 2017.01.11), patent document CN101804155a (a medicine for treating deficiency of both qi and blood caused by radiotherapy and chemotherapy of tumor and postoperative deficiency and a preparation method thereof, 2012.02.01) and the like. The number of traditional Chinese medicines for relieving fatigue, improving immunity, replenishing blood and replenishing qi after chemotherapy is not very large, such as astragalus membranaceus, angelica sinensis, radix dipsaci, prepared rehmannia root, stir-fried Chinese yam, medlar, glossy privet fruit, mulberry fruit, cornus officinalis, donkey-hide gelatin, dried orange peel, moutan bark, jujube and other medicinal materials, which can be known from the patent literature which can be referred to at present. Referring to the related patent documents, most of the formulations currently available in the market for this purpose contain more than 10 to 20 Chinese medicines, or even more. These formulations with large doses often have problems: firstly, the use of a plurality of medicinal materials is difficult to confirm the action mechanism of the effective medicinal materials, so that the dosage and toxicity of the medicinal materials are difficult to control; secondly, the excessive medicinal materials are simply overlapped by the medicinal herbs with similar actions, the compatibility between the medicinal herbs is not considered, and the medicinal herbs are not beneficial to the treatment of diseases, and the prescription is basically difficult to exceed more than ten medicines in classical Chinese medicine ancient books such as Huangdi's internal channel, shang Han miscellaneous diseases theory and the like; thirdly, the use of a plurality of medicinal materials also causes resource waste, which is unfavorable for the control of economic cost and the sustainable development of traditional Chinese medicine.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating qi and blood deficiency symptoms, which is prepared from astragalus, angelica, jujube, medlar and dried orange peel or extracts thereof, wherein the astragalus and the angelica are combined with each other to generate yin and generate qi and blood, and simultaneously, the medlar, the jujube and the dried orange peel are added, so that the traditional Chinese medicine composition has the effects of nourishing liver and kidney, strengthening spleen and regulating qi, tonifying defensive and consolidating exterior and strengthening body resistance, thereby enhancing the immunity of organisms, and is mainly suitable for people with low immunity caused by high working pressure, overfatigue, postpartum qi and blood deficiency and cancer radiotherapy and chemotherapy.
The invention also aims at providing a preparation method of the traditional Chinese medicine composition, which can be used for preparing a compound granule preparation and a paste.
The invention also aims at providing the application of the traditional Chinese medicine composition in preparing a medicine or health care product for treating qi-blood deficiency syndrome.
The invention is realized by the following technical scheme: a traditional Chinese medicine composition for treating qi and blood deficiency syndrome comprises the following components in parts by weight: 25 to 35 parts of astragalus or an extract thereof, 5 to 7 parts of angelica or an extract thereof, 8 to 12 parts of jujube or an extract thereof, 5 to 10 parts of medlar or an extract thereof, and 5 to 8 parts of dried orange peel or an extract thereof.
The traditional Chinese medicine composition at least comprises the following active ingredients: the calycosin glucoside is more than or equal to 0.10mg/g, the astragaloside IV is more than or equal to 0.45mg/g, the ferulic acid is more than or equal to 0.05mg/g, and the matrimony vine polysaccharide is more than or equal to 8.0mg/g.
A preparation method of a traditional Chinese medicine composition for treating qi-blood deficiency syndrome comprises the following steps:
(1) mixing 25-35 parts of astragalus, 5-7 parts of angelica, 8-12 parts of jujube, 5-10 parts of medlar and 5-8 parts of dried orange peel according to parts by weight, adding water, heating, extracting, filtering, concentrating to obtain concentrated solution, and performing the concentrated solution according to the step (2) or the step (3);
(2) Mixing the concentrated solution with adjuvants, heating and stirring to obtain paste of Chinese medicinal composition;
(3) Mixing the concentrated solution with adjuvants, stirring, drying to obtain fine dry powder, squeezing, crushing, and granulating to obtain granule.
In the step (1), the raw materials are soaked in water and then heated to boiling, the micro-boiling is kept for 1.5 to 2 hours, then the filtration is carried out, the filter residues are added with water and heated to boiling, the micro-boiling is kept for 1.5 to 2 hours, then the filtration is carried out, and the two filtrates are combined and then are used for concentration.
In the step (1), the concentrating includes: concentrating the combined filtrate at the vacuum degree of-0.085 to-0.065 Mpa and the temperature of 60-80 ℃ to the relative density of 1.05-1.15, thus obtaining concentrated solution.
In the step (2), the following steps are carried out according to the following steps of 1: mixing the concentrated solution with auxiliary materials in a weight ratio of 0.1-1.0, wherein the auxiliary materials are at least one selected from refined honey or xylitol, maltitol solution and maltose.
In the step (3), the weight ratio is 5-10: 1, mixing the concentrated solution with auxiliary materials, wherein the auxiliary materials are at least one selected from soluble starch and maltodextrin.
An application of the Chinese medicinal composition in preparing medicaments or health-care products for treating qi and blood deficiency syndrome.
Compared with the prior art, the invention has the following advantages:
(1) The invention provides a traditional Chinese medicine composition composed of five medicines or extracts thereof, namely astragalus root, angelica sinensis, chinese date, medlar and dried orange peel, which is developed on the basis of traditional classical formula preparation of 'angelica sinensis blood-replenishing decoction', by combining modern pharmacological research knowledge and assisting with Chinese date, medlar and dried orange peel, and has the effects of effectively treating qi-blood deficiency symptoms, nourishing liver and kidney, strengthening spleen and regulating qi, benefiting sanitation and strengthening exterior and strengthening body resistance, wherein in the effective components, the calycosin glucoside is not lower than 0.10mg/g, the astragaloside is not lower than 0.45mg/g, the ferulic acid is not lower than 0.05mg/g, and the medlar polysaccharide is not lower than 8.0mg/g, and simultaneously, the traditional Chinese medicine composition has good clinical treatment effect.
(2) The traditional Chinese medicine composition disclosed by the invention is prepared by reasonably mixing the Chinese dates, the Chinese wolfberry fruits, the dried orange peels, the astragalus mongholicus and the Chinese angelica, and extracting the extracts by adopting a water extraction process, so that the transfer rate of effective components such as the calycosin glucoside and the astragaloside in the traditional Chinese medicine composition can be effectively improved, the curative effects of treating qi and blood deficiency symptoms of the astragalus mongholicus and the Chinese angelica are fully exerted, and the medication safety is ensured.
(3) The traditional Chinese medicine composition can be applied to preparing medicines or health products for treating qi and blood deficiency symptoms, has a wide application range, can be used for health wine, health medicated diet, health beverage and the like, and has the effects of promoting immunity to improve and relieving fatigue. Is suitable for people with low immunity caused by high working pressure and excessive fatigue, such as post-partum and post-cancer radiotherapy and chemotherapy.
Detailed Description
The objects, technical solutions and advantageous effects of the present invention will be described in further detail below.
It is noted that the following detailed description is exemplary and is intended to provide further explanation of the invention as claimed, and unless otherwise indicated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The traditional classical prescription preparation of the Chinese angelica blood-replenishing decoction is known to have the effects of tonifying qi and producing blood by using astragalus (one for two) and Chinese angelica (wine washing, two for two) for compatibility, but modern medical researches prove that the prescription preparation has the defects of solving the problems of poor appetite, malnutrition and the like when the immunity is low. Although the prior consulted patent literature describes a plurality of pharmaceutical compositions for treating qi and blood deficiency symptoms, the compatibility mechanism of the prescription is not clear, and the instruction for the treatment effect of clinical application is difficult. On the basis of the background, a traditional Chinese medicine composition which can clearly determine the compatibility mechanism of medicines, accurately determine the dosage and the effective components of the medicines, determine the curative effect of the medicines and be applied to clinical practice is needed to be found.
The traditional Chinese medicine composition for treating qi and blood deficiency symptoms comprises 25-35 parts by weight of astragalus membranaceus or an extract thereof, 5-7 parts by weight of angelica sinensis or an extract thereof, 8-12 parts by weight of Chinese date or an extract thereof, 5-10 parts by weight of medlar or an extract thereof and 5-8 parts by weight of dried orange peel or an extract thereof. The Chinese medicinal composition comprises the following active ingredients of more than or equal to 0.10mg/g of calycosin glucoside, more than or equal to 0.45mg/g of astragaloside, more than or equal to 0.05mg/g of ferulic acid and more than or equal to 8.0mg/g of lycium barbarum polysaccharide by mutual combination and compatibility.
The traditional Chinese medicine composition can be paste or granule preparation of the traditional Chinese medicine composition, and is prepared by the following methods:
chinese medicinal composition ointment:
(1) Processing
The astragalus, the angelica, the dried orange peel and the jujube are respectively processed according to the processing requirements of decoction pieces of Chinese pharmacopoeia of 2015 edition:
radix astragali: removing impurities, separating the size, cleaning, moistening, cutting into thick slices (2-4 mm), and drying (70+ -5deg.C).
Chinese angelica root: removing impurities, cleaning, moistening, slicing (1-2 mm), and low-temperature drying (55+ -5 ℃).
Jujube: removing impurities and removing cores.
Dried orange peel: removing impurities, spraying water, moistening thoroughly, shredding, and drying (55+ -5deg.C).
(2) Extraction of
Respectively weighing the processed decoction pieces and the medicinal materials according to the proportion of the formula, adding 12 times of water, soaking for 30 minutes, heating to boil, keeping micro-boiling for 1.5-2 hours, and filtering the filtrate by a 200-mesh filter screen for later use; adding 12 times of water into filter residues, heating to boiling, keeping micro boiling for 1.5-2 h, filtering the filtrate by a 200-mesh screen, and keeping the filtrate for later use; the 2 filtrates were combined.
(3) Concentrating
And uniformly stirring the combined filtrate, concentrating at the vacuum degree of-0.085 to-0.065 Mpa and the temperature of 60-80 ℃ until the relative density is 1.05-1.15 (60-80 ℃), and obtaining concentrated solution.
(4) Preparation of paste
Mixing the concentrated solution with auxiliary materials according to the proportion of 1: mixing the materials according to the weight ratio of 0.1-1.0, heating and stirring the materials uniformly to form paste, and obtaining the paste with the relative density of 1.15-1.40 (60-80 ℃), filling the paste into a container, placing the container into a sterilization tank, and sterilizing the container for 30 minutes at the temperature of 121 ℃ to obtain a paste finished product of the traditional Chinese medicine composition.
In the process, the adjuvant can be refined Mel or at least one of xylitol, maltitol solution and maltose. The method for refining the honey comprises the following steps: heating honey in a pot with strong fire (100-120 ℃), boiling, then taking out floating foam and wax, decocting until the honey-swelled foam is light red and glossy, and twisting with viscous but non-pulled white silk.
The granule of the traditional Chinese medicine composition comprises the following components:
and (3) performing the operation of the step (5) on the concentrated solution in the same way as the steps (1) to (3).
(5) Granule preparation
The obtained concentrated solution and auxiliary materials are mixed according to the proportion of 5 to 10:1, uniformly stirring, freeze-drying or spray-drying the mixture, sieving to obtain fine dry powder, extruding, crushing and granulating the fine dry powder to obtain the required granule, wherein the water content is lower than 6.5%.
In the process, the auxiliary material can be at least one of soluble starch and maltodextrin.
The invention also provides a medicine or health care product for treating qi and blood deficiency syndrome by using the traditional Chinese medicine composition. In practice, the medicament may be administered in the form of tablets, dragees, gelatin capsules, injectable preparations, drinkable suspensions or disintegrable pastes. In one possible embodiment, the medicament may be an effective amount of the Chinese medicinal composition alone or a pharmaceutical composition containing the Chinese medicinal composition, for example, an effective amount of the Chinese medicinal composition is compounded with a pharmaceutically acceptable pharmaceutical carrier to form a pharmaceutical composition. The health product can be used as carrier in the form of tea, wine, bee product, beverage, soup, fresh juice, medicated diet, etc., and has effective content of Chinese medicinal composition as effective component for regulating and improving functions of human body such as deficiency of both qi and blood.
The following description of the invention will be given by way of example only, and the scope of the invention is not limited to the following examples.
Examples 1 to 5:
examples 1 to 5 all relate to a Chinese medicinal composition ointment for treating qi and blood deficiency syndrome.
The preparation method of the traditional Chinese medicine composition ointment is characterized in that the specific technological parameter conditions are shown in the following table 1.
Table 1 preparation process condition parameter table of Chinese medicinal composition paste
Examples 6 to 10:
examples 6 to 10 relate to a Chinese medicinal composition granule for treating qi and blood deficiency syndrome.
The preparation method of the traditional Chinese medicine composition granule is characterized in that the specific technological parameter conditions are referred to in the following table 2.
Table 2 table of parameters of the process conditions for preparing the granules of Chinese medicinal composition
The effective components and the transfer rates of the traditional Chinese medicine composition products in examples 1 to 10 were measured according to the methods described in the following test (one) to test (four), and the specific contents are as follows:
test (one):
calycosin glucoside (C) was carried out on the Chinese medicinal composition products of the above examples 1 to 10 22 H 22 O 10 ) And (5) content measurement.
The measurement is carried out according to high performance liquid chromatography (general rule 0512), and the specific measurement method is as follows:
chromatographic conditions and system suitability test: octadecylsilane chemically bonded silica is used as a filler; gradient elution was performed using acetonitrile as mobile phase a and 0.2% formic acid solution as mobile phase B, as specified in table 3 below; the detection wavelength was 260nm. The theoretical plate number is not less than 3000 calculated by calycosin glucoside peak.
TABLE 3 chromatographic condition parameters
| Time (minutes) | Mobile phase a (%) | Mobile phase B (%) |
| 0～20 | 20～40 | 80～60 |
| 20～30 | 40 | 60 |
Preparation of a control solution: taking a proper amount of calycosin glucoside reference substance, precisely weighing, and adding methanol to prepare a solution containing 50 mug per 1 ml.
Preparation of test solution: about 2g of the preparation is taken, precisely weighed into a 50ml volumetric flask, added with water to be dissolved to the scale, shaken uniformly and filtered, thus obtaining the preparation.
Assay: respectively precisely sucking 10 μl of the reference solution and the sample solution, and injecting into a liquid chromatograph for measurement.
The content of calycosin glucoside in the traditional Chinese medicine composition products in the above examples 1 to 10 is shown in the following table 4.
TABLE 4 Calycosin glucoside content determination Table
And (3) measuring the content of decoction pieces: taking three parts of astragalus decoction pieces, respectively measuring the content of the prepared astragalus decoction pieces according to the decoction piece processing requirements of Chinese pharmacopoeia of 2015 edition, measuring according to high performance liquid chromatography (general rule 0512), and calculating the average value of the content of calycosin glucoside in the three parts of astragalus decoction pieces.
Calycosin glucoside transfer rate calculation: if the content of the calycosin glucoside in the astragalus medicinal material is known to be A%, the transfer rate of the calycosin glucoside=the content of the calycosin glucoside measured by liquid phase per A% of the astragalus dosage x 100% in the traditional Chinese medicine composition product.
The conversion of calycosin glucoside in the traditional Chinese medicine composition products in examples 1 to 10 is calculated as shown in the following table 5.
TABLE 5 Calycosin glucoside conversion determination Table
Test (II):
astragaloside IV (C) was used for the Chinese medicinal composition products of the above examples 1 to 10 41 H 68 O 14 ) And (5) content measurement.
The measurement is carried out according to high performance liquid chromatography (general rule 0512), and the specific measurement method is as follows:
chromatographic conditions and system suitability test: octadecylsilane chemically bonded silica is used as a filler; acetonitrile-water (32:68) as mobile phase; the evaporative light scattering detector detects. The theoretical plate number is not less than 4000 calculated according to astragaloside IV peak.
Preparation of a control solution: taking appropriate amount of astragaloside IV reference substance, precisely weighing, and adding 80% methanol to obtain solution containing 0.5mg per 1 ml.
Preparation of test solution: about 1.0g of the product is taken, the product is placed in a conical flask with a plug, 80% methanol containing 4% of concentrated ammonia test solution is precisely added (4 mL of concentrated ammonia test solution is taken, 80% methanol is added to 100mL and is uniformly shaken), 50mL of the product is sealed, the product is weighed, heated and refluxed for 1 hour, cooled, then the weighed product is weighed, 80% methanol containing 4% of concentrated ammonia test solution is used for supplementing the lost weight, the product is uniformly shaken, filtered, 25mL of continuous filtrate is precisely measured, evaporated to dryness, the residue is dissolved by 80% methanol and is transferred into a 5mL measuring flask, 80% methanol is added to scale, and the product is uniformly shaken, filtered and the continuous filtrate is obtained.
Assay: precisely sucking 5 μl and 10 μl of the reference solution and 10-20 μl of the sample solution respectively, injecting into a liquid chromatograph, measuring, and calculating by external standard two-point logarithmic equation.
The content of astragaloside IV in the traditional Chinese medicine composition products in the above examples 1 to 10 is shown in the following Table 6.
TABLE 6 Astragaloside IV content determination Table
And (3) measuring the content of decoction pieces: taking three parts of astragalus decoction pieces, respectively measuring the content of the prepared astragalus decoction pieces according to the decoction piece processing requirements of Chinese pharmacopoeia of 2015 edition, measuring by a high performance liquid chromatography (general rule 0512), and calculating the average value of the astragaloside IV content in the three parts of astragalus decoction pieces.
Calculating the astragaloside IV transfer rate: when the astragaloside content in the astragalus medicinal material is known to be A%, the astragaloside transfer rate=astragaloside content measured by liquid phase/A% x the astragalus dosage in the traditional Chinese medicine composition product is multiplied by 100%.
The conversion of astragaloside IV in the traditional Chinese medicine composition products in the above examples 1 to 10 is calculated as shown in Table 7 below.
TABLE 7 determination of Astragaloside IV conversion
Test (III):
ferulic acid (C) was used for the Chinese medicinal composition products of examples 1 to 10 10 H 10 O 4 ) And (5) content measurement.
The measurement is carried out according to high performance liquid chromatography (general rule 0512), and the specific measurement method is as follows:
chromatographic conditions and system suitability test: octadecylsilane chemically bonded silica is used as a filler; acetonitrile-0.085% phosphoric acid solution (17:83) is used as a mobile phase; the detection wavelength is 316nm; column temperature was 35 ℃. The theoretical plate number should be not less than 5000 calculated according to ferulic acid peak.
Preparation of a control solution: taking a proper amount of ferulic acid reference substance, precisely weighing, placing into a brown measuring flask, and adding 70% methanol to obtain solution containing 12 μg per 1 mI.
Preparation of test solution: about 1g of the preparation is precisely weighed, placed in a conical flask with a plug, precisely added with 20ml of 70% methanol, sealed, weighed, subjected to ultrasonic treatment for 30 minutes, cooled, weighed again, and subjected to shaking, standing, filtering the supernatant, and collecting the subsequent filtrate.
Assay: respectively precisely sucking 10 μl of the reference solution and the sample solution, and injecting into a liquid chromatograph for measurement.
The contents of ferulic acid in the Chinese medicinal composition products in examples 1 to 10 are shown in Table 8.
TABLE 8 Ferulic acid content determination Table
And (3) measuring the content of decoction pieces: taking three parts of Chinese angelica decoction pieces, respectively measuring the content of the Chinese angelica decoction pieces according to the processing requirements of the Chinese pharmacopoeia of 2015 edition, measuring the content of the Chinese angelica decoction pieces by a high performance liquid chromatography (Tongthen 0512), and calculating the average value of the ferulic acid content in the three parts of Chinese angelica decoction pieces.
Calculating the astragaloside IV transfer rate: given that the ferulic acid content in the angelica medicinal material is A%, the transfer rate of ferulic acid=ferulic acid content measured by liquid phase/A% x the dosage of angelica in the traditional Chinese medicine composition product is multiplied by 100%.
The conversion of ferulic acid in the Chinese medicinal composition products of examples 1 to 10 is calculated as shown in Table 9 below.
TABLE 9 determination of ferulic acid conversion
Test (IV):
the Chinese wolfberry polysaccharide (C) was obtained from the Chinese medicinal composition products of examples 1 to 10 6 H 12 O 6 ) And (5) content measurement.
The specific measurement method is as follows:
preparation of a control solution: taking 25mg of anhydrous glucose reference substance, precisely weighing, placing into a 250ml measuring flask, adding water for dissolving, diluting to scale, and shaking to obtain the final product (each 1ml contains 0.1mg of anhydrous glucose).
Preparation of a standard curve: precisely measuring 0.2ml, 0.4ml, 0.6ml, 0.8ml and 1.0ml of reference substance solution, respectively placing into test tubes with plugs, respectively adding water to 2.0ml, respectively precisely adding 1ml of 5% phenol solution, shaking, rapidly and precisely adding 5ml of sulfuric acid, shaking, standing for 10 min, placing in a water bath at 40 ℃ for 15min, taking out, rapidly cooling to room temperature, taking the corresponding reagent as a blank, measuring absorbance at a wavelength of 490nm according to ultraviolet-visible spectrophotometry (general rule 0401), taking absorbance as an ordinate, taking concentration as an abscissa, and drawing a standard curve.
Assay: about 0.5g of the preparation is taken, precisely weighed, 100ml of 80% ethanol is added, the mixture is heated and refluxed for 1 hour, the mixture is filtered while the mixture is hot, the filter residue and the filter are washed by 30ml of hot 80% ethanol for several times, the filter residue and the filter paper are placed in a flask, 150ml of water is added, and the mixture is heated and refluxed for 2 hours. Filtering while the solution is hot, washing the filter with a small amount of hot water, combining the filtrate and the washing solution, cooling, transferring to a 250ml measuring flask, diluting to a scale with water, shaking, precisely measuring 1ml, placing in a test tube with a plug, adding 1.0ml of water, determining absorbance according to the method under the preparation item of a standard curve from the step of precisely adding 1ml of 5% phenol solution, reading the weight (mg) of glucose in the test solution from the standard curve, and calculating to obtain the glucose-containing solid phase.
The content of Lycium barbarum polysaccharide in the Chinese medicinal composition products of examples 1-10 is shown in Table 10.
Table 10 table for determining polysaccharide content of wolfberry
And (3) measuring the content of decoction pieces: taking three parts of Chinese wolfberry medicinal materials, carrying out content measurement, measuring according to a high performance liquid chromatography (general rule 0512), and calculating the average value of Chinese wolfberry polysaccharide content in the three parts of Chinese wolfberry medicinal materials.
Calculating the astragaloside IV transfer rate: when the content of the lycium barbarum polysaccharide in the known lycium barbarum medicinal material is A%, the transfer rate of the lycium barbarum polysaccharide is measured by liquid phase, namely, the content of the lycium barbarum polysaccharide is/A% multiplied by 100 percent of the dosage of the lycium barbarum in the traditional Chinese medicine composition product.
The conversion rate of Lycium barbarum polysaccharide in the Chinese medicinal composition products in examples 1-10 is calculated as shown in Table 11 below.
Table 11 table for determining conversion of matrimony vine polysaccharide
Comparative example 1:
30g of astragalus and 6g of angelica are taken as prescriptions, and traditional Chinese medicine ointment and traditional Chinese medicine granules are prepared according to the methods and the technological conditions of the embodiment 4 and the embodiment 8 respectively.
The content of calycosin glucoside, astragaloside IV and ferulic acid in the Chinese medicinal paste and granule and their conversion rate were measured in the same manner, as shown in Table 12 below.
Table 12 table for determining the content and conversion
Comparative example 2:
30g of astragalus, 6g of angelica and 7g of dried orange peel are taken as prescriptions, and traditional Chinese medicine ointment and traditional Chinese medicine granules are prepared according to the methods and the technological conditions of the embodiment 4 and the embodiment 8 respectively.
The content of calycosin glucoside, astragaloside IV and ferulic acid in the Chinese medicinal paste and granule and their conversion rate were measured in the same manner, as shown in Table 13 below.
TABLE 13 determination of the content and conversion
Comparative example 3:
the Chinese medicinal paste and the Chinese medicinal granules are prepared by taking 30g of astragalus, 10g of Chinese date and 10g of medlar as prescriptions according to the methods and the process conditions of the embodiment 4 and the embodiment 8 respectively.
The content of calycosin glucoside, astragaloside IV and Lycium barbarum polysaccharide in the Chinese medicinal paste and granule and their conversion rate were measured by the same method, and the contents are shown in Table 14 below.
TABLE 14 determination of the content and conversion
Comparative example 4:
30g of astragalus, 6g of angelica and 10g of medlar are taken as prescriptions, and traditional Chinese medicine ointment and traditional Chinese medicine granules are prepared according to the methods and the technological conditions of the embodiment 5 and the embodiment 9 respectively.
The content and conversion rate of calycosin glucoside, astragaloside IV, ferulic acid and Lycium barbarum polysaccharide in the Chinese medicinal paste and granule were determined by the same method, and are shown in Table 15 below.
TABLE 15 determination of the content and conversion
Comparative example 5:
the traditional Chinese medicine ointment and the traditional Chinese medicine granule are prepared by taking 30g of astragalus, 10g of medlar, 10g of Chinese yam, 6g of angelica, 15g of ginseng, 5g of fructus amomi, 6g of jujube kernel and 3g of mulberry as prescriptions according to the method and the technological conditions of the embodiment 5 and the embodiment 9 respectively.
The content and conversion rate of calycosin glucoside, astragaloside IV, ferulic acid and Lycium barbarum polysaccharide in the Chinese medicinal paste and granule were determined by the same method, and are shown in Table 16 below.
TABLE 16 determination of the content and conversion
Comparative example 4:
prepared rehmannia root, chinese yam, medlar, dogwood fruit, twotooth achyranthes root, chinese dodder seed, rhodiola root, indian buead, ginseng, cassia bark, eucommia bark, himalayan teasel root, chinese taxillus herb, red paeony root, white paeony root, prepared liquorice and szechuan lovage rhizome are respectively used as prescriptions, and traditional Chinese medicine ointment and traditional Chinese medicine granule are respectively prepared according to the methods and the technological conditions of the embodiment 4 and the embodiment 8.
The content and conversion rate of calycosin glucoside, astragaloside IV, ferulic acid and Lycium barbarum polysaccharide in the Chinese medicinal paste and granule were determined by the same method, and are shown in Table 17 below.
TABLE 17 determination of the content and conversion
In recent years, clinical and academia continuously enhances the rationality and scientific importance of the compatibility of the traditional Chinese medicines, and modern scientific technologies such as molecular biotechnology, chemical analysis technology and the like also provide guidance for the reasonable compatibility of the traditional Chinese medicines. The research shows that the traditional Chinese medicines matched according to different proportions have certain difference in chemical component content. Meanwhile, as a large number of medicine compatibility plays roles of replenishing blood and replenishing qi, improving immunity and relieving fatigue in related research reports and patents, in order to further research the rationality of the compatibility of the traditional Chinese medicine composition related to the invention, the above comparative examples 1-4 are specially used for researching the influence of effective components aiming at related formulas under different compatibility so as to establish a content measuring method in the traditional Chinese medicine composition, respectively measuring the content of effective components such as calycosin glucoside, astragaloside and the like, and simultaneously calculating the corresponding conversion rate.
Comparing the above-determined effective component contents and conversion rates of the traditional Chinese medicine composition products in examples 1 to 10 with those of the traditional Chinese medicine paste and the traditional Chinese medicine granule in comparative examples 1 to 4, it can be known that the pharmacological effect is achieved by simply using components of which 2 or 3 of the five medicinal materials cannot achieve the optimal transfer in the prescription products obtained by adopting the compatibility of astragalus, angelica, jujube, medlar and dried orange peel, and the pharmacological effect can be proved by the following experimental study.
Clinical study
The experimental group invites a plurality of female subjects who are in the syndrome of deficiency of both qi and blood by the differentiation of traditional Chinese medicine to participate, and the traditional Chinese medicine compatibility with the functions of replenishing blood and replenishing qi and relieving fatigue is adopted to carry out the comparative clinical study with the medicine taste of the formula.
Prescription one: 30g of astragalus, 6g of angelica, 10g of jujube, 8g of medlar and 6g of dried orange peel (the prescription dosage is referred to in example 4);
prescription II comprises 30g of astragalus root and 6g of angelica (the prescription dosage refers to comparative example 1);
prescription III: 30g of astragalus, 10g of medlar, 10g of yam, 6g of angelica, 15g of ginseng, 5g of fructus amomi, 6g of jujube kernel and 3g of mulberry (the prescription dosage refers to comparative example 5);
prescription IV: radix rehmanniae Preparata, rhizoma Dioscoreae, fructus Lycii, corni fructus, achyranthis radix, semen Cuscutae, radix Rhodiolae, poria, ginseng radix, cortex Cinnamomi, eucommiae cortex, radix Dipsaci, herba Taxilli, radix Paeoniae Rubra, radix Paeoniae alba, radix Glycyrrhizae Preparata, and rhizoma Ligustici Chuanxiong each 5g.
The subjects were divided into 4 groups of 5 subjects each, and each group was taken for 2 weeks, 1 dose daily, and 3 times per day according to the above prescription. The improvement of symptoms of both qi and blood deficiency of each group was observed, see table 18 below.
Clinical comparison of qi and blood deficiency of different prescriptions of Table 18
| Prescription name | Degree of improvement of dizziness | Palpitation and shortness of breath improvement | Improvement degree of complexion | Menstrual periodDegree of abnormality improvement | Total effective rate |
| Prescription of prescriptionA first part | 4 | 4 | 5 | 5 | 18 |
| Prescription two | 4 | 4 | 4 | 4 | 16 |
| Prescription III | 3 | 4 | 5 | 4 | 15 |
| Prescription IV | 3 | 4 | 4 | 3 | 14 |
Remarks: the improvement degree is calculated by average division of 5, wherein 1-2 are divided into general; 3-4 are classified as good; 5 is divided into basic cure.
In summary, clinical studies show that compared with the larger prescription III and the larger prescription IV, the prescription I and the prescription II only adopt the prescription with less medicine flavor and still can exert better blood replenishing and qi replenishing effects. Meanwhile, compared with the prescription I and the prescription II, the prescription which is prepared from astragalus and angelica, astragalus, angelica, jujube, medlar and dried orange peel has certain advantages in improving series of symptoms caused by deficiency of both qi and blood. Therefore, the prescription with the formula has obvious clinical effect on the treatment of qi and blood deficiency.
Pharmacological experiment study
In order to further prove the accuracy of the prescription for taking the medicine, the experimental group respectively carries out prescription disassembly and flavor adding on the prescription and carries out pharmacological experimental comparison.
Prescription one: 30g of astragalus, 6g of angelica, 10g of jujube, 8g of medlar and 6g of dried orange peel (the prescription dosage is referred to in example 4);
prescription II: 30g of astragalus and 6g of angelica (prescription dosage is referred to comparative example 1);
prescription five: 10g of jujube, 10g of medlar and 7g of dried orange peel;
prescription six: 30g of astragalus, 6g of angelica, 10g of jujube, 10g of medlar, 7g of dried orange peel, 6g of prepared rhizome of rehmannia, 10g of yam and 6g of mistletoe.
(1) Anti-fatigue test of mice
(1.1) laboratory animals
Male Kunming mice weighing 18-22 g.
Instrument and reagent: each prescription concentrate is prepared by a laboratory; SOD kit and MDA kit are all purchased from Nanjing to build biological engineering institute.
Preparing concentrated solutions of all prescriptions: each prescription is respectively weighted according to the prescription compatibility condition by 30 times, each decoction piece is respectively weighed, mixed and stirred uniformly, the prescription quantity of water is added by 12 times, the decoction is decocted for 2 times, each time lasts for 90 minutes, the filtration is carried out, and the two filtrates are combined. Mixing the obtained extractive solutions, and concentrating to obtain concentrated solution with crude drug content of 1.2-1.5 g/mL.
SOD, MDA content assay: the method comprises the steps of selecting 50 Kunming mice, wherein the male weight is 18-22 g, the weight is randomly divided into 5 groups, and each group comprises 10 mice, namely a prescription group, a prescription group five, a prescription group six and a blank control group. The mice were given their body weight by gavage, the blank group was given the same volume of distilled water, and were continuously gavaged for 30d, and after gavage for 30min on day 30, the body weight of each mouse was weighed. Taking blood by means of blood taking from eyeballs of mice, collecting the obtained whole blood by using a 1.5mLEP tube without anticoagulant, standing for 3 hours at a refrigerator of 4 ℃ for blood coagulation, centrifuging for 15 minutes at 3500r/min, taking serum, and respectively detecting SOD activity and MDA content in serum of each group of mice according to an SOD test box and an MDA test box.
The analysis method comprises the following steps: data were processed using SPSSl7.0 software and Excel analysis, calculated results were expressed as (x+ -s), statistical analysis was performed between groups, and P < 0.05 was statistically significant.
Results and analysis: the MDA content in serum of mice in the fifth and sixth prescriptions is not significantly different (P > 0.05) compared with that of the blank control group, but the MDA content of the mice in the whole administration group tends to be reduced; the SOD activity of the two and six mice in the prescription is obviously improved (P < 0.05) compared with that of the blank control group, the SOD activity of the one mice in the prescription is obviously improved (P < 0.01) compared with that of the blank control group, and the SOD activity of the five mice in the prescription is not obviously different (P > 0.05) compared with that of the blank control group, see the following table 19.
Table 19 comparison of the effect of different prescriptions on SOD activity and MDA content in mice (x±s, n=10)
| Group of | MDA content nmol/ml | SOD activity capability mu/ml |
| Blank control group | 12.78±0.17 | 4.56±0.129 |
| Prescription group | 10.15±0.3＊ | 5.76±0.62＊＊ |
| Prescription two sets | 10.65±1.91＊ | 5.35±1.02＊ |
| Prescription five groups | 11.23±2.18 | 4.79±0.007 |
| Prescription six sets | 10.98±1.02 | 5.03±0.741＊ |
Note that: compared with the blank control group, P < 0.05 and P < 0.01.
According to the comprehensive comparison of the pharmacological experimental data, the effect of the prescription is poorer than that of the prescription with the medicinal flavor after the prescription is disassembled and flavored, the MDA content is reduced, the SOD activity is improved, and the accuracy of the prescription administration can be illustrated to a certain extent.
And (III) selection of metering.
The secret of the traditional Chinese medicine is the dosage, the theory, the method, the prescription and the medicine are throughout the whole process of dialectical treatment of the traditional Chinese medicine, and the accurate preparation of the prescription dosage is a key link. The composition of the prescription has strict principle, the compatibility of monarch, minister, assistant and guide is required to be followed, and meanwhile, the prescription has great flexibility, and the functions and indications of the prescription are quite different due to slightly changed dosage of the medicines in many times. As described in ancient books: both of the two formulas are prepared by combining the immature bitter orange for promoting qi circulation and the bighead atractylodes rhizome for replenishing qi to invigorate the spleen, the immature bitter orange in the immature bitter orange soup is heavier than the bighead atractylodes rhizome, and the immature bitter orange is used for resolving the deficiency and is mainly for resolving the deficiency and is suitable for the syndrome of qi stagnation and water retention and heart depression and hard mass; while Zhishu pill has the effect of reinforcing the weight of the bighead atractylodes rhizome more than that of the immature bitter orange and reinforcing the weight of the bighead atractylodes rhizome more than that of the Chinese medicinal herb, and is mainly used as the pill, and is suitable for spleen deficiency and qi stagnation and food stagnation with chest and epigastrium fullness. For example, the formula of the decoction is composed of four medicines of leech, tabanus, rheum officinale and peach kernel. The decoction is mainly used for treating severe symptoms of lower jiao and blood accumulation, fever, hard lower abdomen and spontaneous urination, and mania or mania; the pill is prepared by the same amount of leech and Tabanus, the same amount of rheum officinale and the same amount of peach kernel, and is mainly used for treating the symptom of lower jiao blood accumulation, wherein the symptom is that the lower abdomen is full and not hard, urine is self-friendly and no mania exists.
Astragalus root, chinese angelica root, chinese date, matrimony vine and dried orange peel can be used for tonifying qi and blood and replenishing qi to invigorate spleen in the theoretical guidance of traditional Chinese medicine. However, in terms of dosage composition, the traditional Chinese medicine composition related to the application is prepared according to the strict compatibility of the used functional symptoms, and has accurate dosage and obvious curative effect. In order to further verify the dosage preference, the experimental group adopts to establish a compound anemia model and a post-chemotherapy anemia animal model to examine the blood replenishing effect of the compound anemia model and the post-chemotherapy anemia animal model under different dosages.
Prescription one: 30g of astragalus, 6g of angelica, 10g of jujube, 8g of medlar and 6g of dried orange peel (the prescription dosage is referred to in example 4);
prescription seven: 10g of astragalus, 10g of angelica, 5g of jujube, 5g of medlar and 10g of dried orange peel;
prescription eight: 12g of astragalus, 6g of angelica, 20g of jujube, 20g of medlar and 7g of dried orange peel;
(1) Experimental materials
SPF-class healthy BALB/C mice, 200, male and female halves, and the weight is 18-22 g.
And (3) molding agent: cyclophosphamide (0.2 ml/branch) for injection, manufactured by shanxi-tai-flourishing pharmaceutical company limited (national standard H18010373). EDTA-ka2 anticoagulant is available from Boshide cattle technology Co.
Full-automatic multi-species animal blood analyzer (supplied by rapson medical instruments, china).
(2) Animal model
(1) Establishing a composite blood loss anemia animal model: except for the normal groups, the mice in each group are exsanguinated for 0.4ml in 1-3 days, 0.3ml in 4-5 days and 0.4ml in 6-7 days; and adopting a daily fasted method. The molding cycle was 12 days.
(2) Establishing a chemotherapy anemia animal model: except for the normal group, cyclophosphamide was injected intraperitoneally at 200mg/kg body weight dose every day for 1d and 3d for each group of mice; cyclophosphamide is injected intraperitoneally at a dose of 100mg/kg body weight daily for 5d and 7 d. A total of 4 injections. The molding cycle was 14 days.
(3) Preparation method of different prescriptions
Each prescription is respectively weighted according to the prescription compatibility condition by 30 times, each decoction piece is respectively weighed, mixed and stirred uniformly, the prescription quantity of water is added by 12 times, the decoction is decocted for 2 times, each time lasts for 90 minutes, the filtration is carried out, and the two filtrates are combined. Mixing the obtained extractive solutions, and concentrating to obtain concentrated solution with crude drug content of 1.2-1.5 g/mL.
(4) Detection index
(4.1) general observations: (1) daily performance: whether there are symptoms such as hypokinesia, slow action, slow reaction, reduced eating, loose stool, wilt of hair color, and binding. (2) Weight of: body weight is one of the important signs of disease development and progression. The body weight of the mice was measured 1 time before the experiment, 1 week after the molding, and 2 weeks to observe the effects of starvation, bleeding, and chemotherapy on the body weight of the mice.
(4.2) peripheral blood cell count: and (3) respectively taking 60ul of blood from the orbit vein of the mouse before, during and after the molding period, adding the blood into a test tube with EDTA-ka2 solid anticoagulant, fully mixing the blood with the anticoagulant, and detecting by adopting a full-automatic hemocytometer.
(5) Statistical method
The data were processed using SPSS17.0 software and Excel analysis, the calculated results were expressed as (x+ -s), statistical analysis was performed between groups, and P < 0.05 was statistically significant.
(6) Results and analysis
(6.1) influence of different doses on general conditions of Experimental anemia model mice
(6.1.1) effects on behaviour of mice in the anaemia model: the compound anemia group starts to have the phenomena of activity reduction, binding pile preference, arch back, vertical hair, unsmooth hair and the like at the 7 th day after molding. Chemotherapy anaemia group: the phenomena of activity reduction, binding pile preference, arch back, vertical hair, rough hair and the like begin to appear at the 9 th day after molding. The symptoms were alleviated to different extents after treatment of mice in each group at different doses for one week.
(6.1.2) effect on body weight of mice in the anemia model: the effects of different doses on the weights of mice with anemia complex and anemia chemotherapy are shown in tables 20 and 21.
Table 20 effects on Compound anemia model mice body weight (g, χ+ -s, n=10)
| Group of | Before molding | Moulding treatment for 1 week | Treatment for 2 weeks |
| Normal group | 20.93±2.03 | 21.03±0.92 Δ | 21.32±0.37 Δ |
| Model group | 21.39±1.18 | 20.36±1.01 * | 17.69±1.21 * |
| Prescription group | 21.06±0.85 | 21.23±0.36 | 21.30±0.72 *Δ |
| Prescription seven groups | 21.33±0.81 | 20.15±0.63 | 20.63±0.45 Δ |
| Prescription eight groups | 21.15±0.92 | 20.80±0.25 | 20.90±0.56 Δ |
Note that: comparison with the Normal group * P is less than 0.05; comparison with model groupIn comparison with the prior art, the method has the advantages that, △ P＜0.05。
table 21 effects on body weight of mice model for chemotherapy anemia (g, χ.+ -. S, n=10)
| Group of | Before molding | Moulding treatment for 1 week | Treatment for 2 weeks |
| Normal group | 21.13±1.69 | 21.22±0.79 Δ | 21.25±1.02 Δ |
| Model group | 21.29±0.75 | 20.41±0.93 * | 18.00±0.33 * |
| Prescription group | 21.76±1.13 | 21.35±0.36 | 22.25±1.67 *Δ |
| Prescription seven groups | 21.13±1.58 | 20.53±2.73 | 20.60±1.92 Δ |
| Prescription eight groups | 21.45±0.47 | 20.01±1.92 | 19.93±1.83 Δ |
Note that: comparison with the Normal group * P is less than 0.05; in comparison with the set of models, △ P＜0.05。
the experimental data can be used for knowing that the first prescription, the seventh prescription and the eighth prescription can slow down the descending trend of the weight of the mice in the anemia model group to a certain extent, the first prescription, namely the prescription of the application, has obvious advantages in recovering the weight of the mice in the anemia model group, and the data has statistical significance (P is less than 0.05).
(6.1.3) effect on peripheral blood of mice with anemia model: the compound anemia group takes the erythrocyte count as an evaluation index, and the chemotherapy anemia group takes the white blood cell count as an evaluation index, and the optimal ratio in terms of improving the peripheral blood cell count is compared under different dosage ratios. The results are shown in Table 22 below.
Table 22 influence of different dose ratios on peripheral blood cells of anemia model (χ±s, n=10)
Note that: comparison with the Normal group * P is less than 0.05; in comparison with the set of models, △ P＜0.05。
according to the analysis of the experimental data, compared with a normal group, the peripheral red blood cell count of the mice in the compound anemia model group is obviously reduced, and the compound anemia model group has statistical significance (P is less than 0.05), and can obviously improve the peripheral red blood cell count of the mice under the dosage proportion of the compound anemia model group; meanwhile, compared with a normal group, the cell count of Zhou Baigong outside mice in a chemotherapy anemia model group is obviously reduced, and the cell count of Zhou Baigong outside the mice can be obviously improved under the dosage proportion of the formula with statistical significance (P is less than 0.05).
In conclusion, the experimental result of the anemia model shows that the dosage of 30g of astragalus, 6g of angelica, 10g of jujube, 8g of medlar and 6g of dried orange peel (namely, the prescription I) has obvious advantages in improving the weight of mice and increasing the number of peripheral blood cells, and the accuracy and the advantage of the dosage proportion of the prescription are proved.
The foregoing description is only a preferred embodiment of the present invention, and is not intended to limit the present invention in any way, and any simple modification, equivalent variation, etc. of the above embodiment according to the technical matter of the present invention fall within the scope of the present invention.
Claims (4)
1. A method for preparing a traditional Chinese medicine composition for improving body weight in qi-blood deficiency syndrome is characterized by comprising the following steps: the method comprises the following steps:
the method comprises the steps of (1) mixing, by weight, 25-35 parts of astragalus membranaceus, 5-7 parts of angelica sinensis, 8-12 parts of Chinese date, 5-10 parts of medlar and 5-8 parts of dried orange peel, adding water for soaking, heating to boil, keeping micro-boiling for 1.5-2 hours, filtering, adding water into filter residues, heating to boil, keeping micro-boiling for 1.5-2 hours, filtering, combining two filtrates, concentrating, and concentrating the combined filtrate at a vacuum degree of-0.085 to-0.065 Mpa and a temperature of 60-80 ℃ to a relative density of 1.05-1.15 to obtain a concentrated solution, wherein the concentrated solution is prepared according to the step (2) or the step (3);
(2) According to the following steps of 1: mixing the concentrated solution and auxiliary materials in a weight ratio of 0.1-1.0, heating and stirring to obtain paste of the traditional Chinese medicine composition;
(3) According to the weight ratio of 5-10: 1, mixing the concentrated solution with auxiliary materials in a weight ratio, uniformly stirring, drying to obtain fine dry powder, extruding, crushing and granulating the fine dry powder to obtain granules of the traditional Chinese medicine composition,
the ointment or granule of the traditional Chinese medicine composition meets the following indexes: the calycosin glucoside is more than or equal to 0.10mg/g, astragaloside IV is more than or equal to 0.45mg/g, ferulic acid is more than or equal to 0.05mg/g, and Lycium barbarum polysaccharide is more than or equal to 8.0mg/g.
2. The method according to claim 1, characterized in that: in the step (2), the auxiliary material is selected from at least one of refined honey or xylitol, maltitol solution and maltose.
3. The method according to claim 1, characterized in that: in the step (3), the auxiliary material is at least one selected from soluble starch and maltodextrin.
4. A Chinese medicinal composition for improving body weight in qi-blood deficiency syndrome prepared by the method of any one of claims 1 to 3.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911298448.5A CN112972547B (en) | 2019-12-17 | 2019-12-17 | Traditional Chinese medicine composition for treating qi and blood deficiency syndrome and preparation method and application thereof |
| PCT/CN2020/130097 WO2021120972A1 (en) | 2019-12-17 | 2020-11-19 | Traditional chinese medicine composition for treating deficiency of both qi and blood, preparation method therefor and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911298448.5A CN112972547B (en) | 2019-12-17 | 2019-12-17 | Traditional Chinese medicine composition for treating qi and blood deficiency syndrome and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112972547A CN112972547A (en) | 2021-06-18 |
| CN112972547B true CN112972547B (en) | 2024-03-29 |
Family
ID=76341875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911298448.5A Active CN112972547B (en) | 2019-12-17 | 2019-12-17 | Traditional Chinese medicine composition for treating qi and blood deficiency syndrome and preparation method and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112972547B (en) |
| WO (1) | WO2021120972A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109938343A (en) * | 2019-04-03 | 2019-06-28 | 江西安顺堂生物科技有限公司 | A kind of kidney tonifying is qi-blood tonifying, antioxidant and anti-aging, improves endocrine health care product |
| CN113616600B (en) * | 2021-08-05 | 2023-07-14 | 广东汇群中药饮片股份有限公司 | Chinese medicinal compound granule for treating spleen and lung qi deficiency and preparation method thereof |
| CN115487247B (en) * | 2022-11-04 | 2023-06-16 | 杭州市中医院 | Traditional Chinese medicine composition and process for treating threatened abortion |
| CN116008134B (en) * | 2023-03-27 | 2023-06-09 | 青州尧王制药有限公司 | Identification method of malt, roasted malt and scorched malt formula particles |
| CN116898897B (en) * | 2023-08-08 | 2024-01-26 | 万泰元经典名方汤饮料(香港)有限公司 | Primordial qi-tonifying, hypoxia-resisting and chronic fatigue-conditioning primordial qi-preserving soup recipe and preparation method thereof |
| CN117427142B (en) * | 2023-12-01 | 2024-03-19 | 武汉森澜生物科技有限公司 | Composition for replenishing blood, replenishing qi, regulating menstruation and maintaining beauty and preparation method thereof |
| CN117398400B (en) * | 2023-12-15 | 2024-03-15 | 吉林敖东集团力源制药股份有限公司 | Pharmaceutical composition for treating anemia |
| CN117904034A (en) * | 2024-01-19 | 2024-04-19 | 杏林医学科技(江苏)有限公司 | Autologous stem cell culture solution and application thereof in gel for repairing female reproductive organs |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111437318A (en) * | 2020-06-03 | 2020-07-24 | 四川新绿色药业科技发展有限公司 | Traditional Chinese medicine soft extract for treating qi-blood deficiency syndrome and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104560551B (en) * | 2014-12-19 | 2016-05-11 | 杨毅 | A kind of drink and preparation method with benefiting qi and nourishing blood effect |
| CN104436148A (en) * | 2014-12-29 | 2015-03-25 | 张震 | Traditional Chinese medicine composition for treating hypotension caused by qi-blood deficiency |
| CN104922295A (en) * | 2015-05-25 | 2015-09-23 | 上海焦点生物技术有限公司 | Blood-nourishing and blood-enriching traditional Chinese medicine composition |
-
2019
- 2019-12-17 CN CN201911298448.5A patent/CN112972547B/en active Active
-
2020
- 2020-11-19 WO PCT/CN2020/130097 patent/WO2021120972A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111437318A (en) * | 2020-06-03 | 2020-07-24 | 四川新绿色药业科技发展有限公司 | Traditional Chinese medicine soft extract for treating qi-blood deficiency syndrome and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 乌日根等.芪归扶正颗粒剂水提工艺的优化.内蒙古医学院学报.2012,-(34),第765-767页. * |
| 李伯川.眩晕证治.四川中医.1988,-(02),第28页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112972547A (en) | 2021-06-18 |
| WO2021120972A1 (en) | 2021-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112972547B (en) | Traditional Chinese medicine composition for treating qi and blood deficiency syndrome and preparation method and application thereof | |
| US10813964B2 (en) | Shenlingbaizhu granules and preparation method thereof | |
| CN100548323C (en) | A kind of pharmaceutical composition of making by Herb Gynostemmae Pentaphylli, Radix Panacis Quinquefolii and the Radix Astragali | |
| CN102846846B (en) | Donkey-hide gelatin paste and preparation method thereof | |
| CN101856450B (en) | Chinese medicinal composition for treating diabetic nephropathy | |
| CN102397372A (en) | Medicinal composition and pharmaceutical preparation and application thereof to treating irritable bowel syndrome | |
| CN102380061A (en) | Chinese medicinal composition for eliminating and dissolving phlegm and relieving cough, as well as preparation method and application thereof | |
| CN102178733B (en) | Chinese medicinal preparation for treating diabetes and preparation method thereof | |
| CN109512857A (en) | A kind of mannose-Chinese herbal compounds inhibiting tumour growth | |
| CN103191298A (en) | Traditional Chinese medicinal composition for treating blood group incompatibility haemolytic disease and preparation method thereof | |
| CN111437318A (en) | Traditional Chinese medicine soft extract for treating qi-blood deficiency syndrome and preparation method thereof | |
| CN101199735A (en) | Medicament compound for treating children ADHD and preparing method thereof | |
| CN105582274A (en) | Pharmaceutical composition for treating female climacteric syndrome and preparing method thereof | |
| CN110917311A (en) | A Chinese medicinal oral liquid for preventing miscarriage and regulating menstrual period and climacteric period, and its preparation method | |
| CN104958615B (en) | A kind of Chinese medicine composition of prevention and treatment II diabetes and preparation method thereof | |
| CN105147996B (en) | Kidney-tonifying marrow-benefiting hematogenesis prescription and preparation method of paste and granules thereof | |
| CN102698099A (en) | Pill for treating diabetes mellitus | |
| CN107823487B (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease and preparation method and application thereof | |
| CN114259540B (en) | Traditional Chinese medicine composition for treating diabetes with syndrome of deficiency of both qi and yin and preparation method and application thereof | |
| CN114732876B (en) | Traditional Chinese medicine composition for treating type II diabetes | |
| CN114796417B (en) | Blood sugar reducing traditional Chinese medicine formula and preparation method thereof | |
| CN107007721B (en) | Traditional Chinese medicine compound preparation for treating anemia caused by qi deficiency of spleen and kidney and preparation method | |
| CN116942771B (en) | Traditional Chinese medicine composition for treating coronary heart disease and application thereof | |
| CN107137557B (en) | Chinese medicinal compound preparation for treating anemia caused by deficiency of vital energy and essence and preparation method thereof | |
| CN105596663A (en) | Weight-losing drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |